Get the Stockscreener App
1.03
0.98%
0.01
After Hours:
.98
-0.05
-4.85%
Lexaria Bioscience Corp stock is traded at $1.03, with a volume of 99,409.
It is up +0.98% in the last 24 hours and up +47.14% over the past month.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
See More
Previous Close:
$1.02
Open:
$1.04
24h Volume:
99,409
Relative Volume:
0.56
Market Cap:
$25.63M
Revenue:
$368.00K
Net Income/Loss:
$-9.54M
P/E Ratio:
-2.1512
EPS:
-0.4788
Net Cash Flow:
$-9.47M
1W Performance:
+7.83%
1M Performance:
+47.14%
6M Performance:
+21.45%
1Y Performance:
-27.97%
1-Day Range:
$0.9711
$1.04
1-Week Range:
$0.8713
$1.06
52-Week Range:
$0.46
$1.69
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Name
Lexaria Bioscience Corp
Sector
Industry
Phone
250-765-6424
Address
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
1.03 | 25.39M | 368.00K | -9.54M | -9.47M | -0.4788 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lexaria Bioscience Corp Stock (LEXX) Latest News
Lexaria Bioscience (LEXX) Initiates 2026 Animal Study for Enhanced Formulations - GuruFocus
Lexaria Launches New GLP-1 Study to Expand Drug Delivery IP - TipRanks
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property - Weatherford Democrat
Lexaria lines up rat study to test drug formulas for new patents - Stock Titan
Lexaria Bioscience Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2026 - marketscreener.com
Lexaria Bioscience Corp reports results for the quarter ended February 28Earnings Summary - TradingView — Track All Markets
LEXARIA BIOSCIENCE ($LEXX) Releases Q2 2026 Earnings - Quiver Quantitative
Lexaria 10-Q: Revenue $0.02M, EPS $(0.13) for Six Months Ended Feb 28, 2026 - TradingView — Track All Markets
Lexaria Bioscience (NASDAQ: LEXX) revenue plunges as going concern risk emerges - Stock Titan
Lexaria Bioscience Corp.Warrant (NQ: LEXXW - FinancialContent
Lexaria Bioscience announces $2M registered direct offering; shares slip 19% - MSN
Lexaria Bioscience Corp expected to post a loss of 9 cents a shareEarnings Preview - TradingView — Track All Markets
Published on: 2026-04-09 10:10:06 - baoquankhu1.vn
Short Covering: Can Lexaria Bioscience Corp sustain its profitabilityRisk Management & Long Hold Capital Preservation Plans - baoquankhu1.vn
Quarterly Risk: Can Lexaria Bioscience Corp Equity Warrant sustain earnings growthGap Up & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
LEXX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Lexaria Bioscience Corp. (LEXX) Stock: Oral Obesity Drug Momentum Fuels Innovation Outlook - parameter.io
Lexaria Eyes Growing Oral GLP-1 Market After Eli Lilly’s Foundayo Approval - TipRanks
Lexaria Applauds Eli Lilly's Foundayo Drug Approval - Investing News Network
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval - The Joplin Globe
Portfolio Shifts: What hedge funds are buying CSBRBuy Signal & Reliable Breakout Forecasts - baoquankhu1.vn
Lexaria signs contract for semaglutide drug delivery study By Investing.com - Investing.com South Africa
LEXX Technical Analysis & Stock Price Forecast - Intellectia AI
Lexaria Bioscience Corp. (LEXX) Stock Price, News, Quote & History - ca.finance.yahoo.com
Lexaria Launches New Human Trial to Advance Oral GLP-1 Drug Delivery Platform - TipRanks
Aug Retail: Will Lexaria Bioscience Corp Equity Warrant outperform tech stocks2026 Major Catalysts & Smart Investment Allocation Tips - baoquankhu1.vn
Lexaria to Begin New Human Clinical Study in GLP-1 - Investing News Network
Lexaria signs contract for semaglutide drug delivery study - Investing.com
Lexaria Bioscience to Launch New Clinical Study Comparing Enhanced Oral GLP-1 Formulations to Market Leaders - citybuzz -
Lexaria Bioscience (LEXX) Launches Key Human Pilot Study - GuruFocus
A 5-week human trial will test Lexaria's oral GLP-1 against Wegovy - Stock Titan
Can Lexaria Bioscience Corp sustain its profitability2026 Weekly Recap & Community Consensus Trade Alerts - baoquankhu1.vn
Lexaria Bioscience files to sell 2.76M shares of common stock for holders - MSN
Sentiment Review: What is Lexaria Bioscience Corp Equity Warrants revenue forecastDividend Hike & High Accuracy Trade Alerts - baoquankhu1.vn
Institution Moves: Can Lexaria Bioscience Corp lead its sector in growth - baoquankhu1.vn
History Review: What hedge funds are buying Lexaria Bioscience Corp2026 Highlights & Capital Efficient Trading Techniques - baoquankhu1.vn
Risk Analysis: Can Lexaria Bioscience Corp expand into new marketsEarnings Beat & High Conviction Trade Alerts - baoquankhu1.vn
Weekly Earnings: Can Lexaria Bioscience Corp sustain its profitability2026 Action & Verified Short-Term Plans - baoquankhu1.vn
Lexaria receives 5 patents including 2 for diabetes treatment By Investing.com - Investing.com Australia
Stock Recap: Will Lexaria Bioscience Corp Equity Warrant face regulatory challenges2026 PreEarnings & Entry and Exit Point Strategies - baoquankhu1.vn
Lexaria Bolsters Global Patent Portfolio With New GLP-1 and Cardiometabolic IP - TipRanks
Lexaria's Robust Patent Portfolio Continues to Grow - Investing News Network
LEXX Advances with New Patents for Hypertension, Epilepsy, and D - GuruFocus
Lexaria receives 5 patents including 2 for diabetes treatment - Investing.com
Five new patents extend Lexaria's diabetes and epilepsy claims into 2044 - Stock Titan
FOMO Trade: How does Lexaria Bioscience Corp correlate with Nasdaq2026 Momentum Check & Consistent Return Strategy Ideas - baoquankhu1.vn
Aug Intraday: How does Lexaria Bioscience Corp correlate with Nasdaq2026 Market Mood & Daily Entry Point Alerts - baoquankhu1.vn
Moving Averages: Will Lexaria Bioscience Corp Equity Warrant stock go up in YEARShare Buyback & Daily Entry Point Alerts - baoquankhu1.vn
Lexaria pursues oral GLP-1 drug delivery partnerships By Investing.com - Investing.com Australia
If You Invested $1,000 in Lexaria Bioscience Corp (LEXX) - Stock Titan
Lexaria Targets Booming GLP-1 Market With Enhanced Oral Drug Platform - tipranks.com
Lexaria Bioscience Corp Stock (LEXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):